Partner, Athyrium Capital Management, LP
Richard Pines helped form Athyrium in 2008 and currently serves as a Partner.
expertise lies in sourcing and identifying attractive investment opportunities through his
deep network of contacts within the healthcare industry.
has been involved in every stage of the investment process including negotiating, structuring, executing and monitoring new investments.
time at Athyrium, he
led the following investments: BioFire Diagnostics, Verenium, Tria Beauty
, Universal Biosensors, Retrophin, Synarc-Biocore, Apollo Endosurgery, Cipher Pharmaceuticals and HLS Therapeutics.
From 2005 to 2008, Mr. Pines worked at Barclays Capital
and as part of the Lehman Brothers
Global Trading Strategies life sciences team.
While at Lehman Brothers
had substantial involvement in the equity and structured investments life sciences portfolio.
Representative structured investments include companies such as Jazz Pharmaceuticals
, ISTA Pharmaceuticals
, Nektar Therapeutics
Representative equity investments include companies such as Sequenom
, Incyte Corporation
, Acorda Therapeutics
and Penwest Pharmaceuticals
Prior to Lehman, he
was an Analyst in Credit Suisse's
Investment Banking Division focused on healthcare clients.
Mr. Pines worked in a traditional healthcare coverage role before moving to a product group called the Buyside Insights Group, which provided strategic insights to the firm's clients utilizing a value-based framework.
Mr. Pines graduated with a B.S. in both Accounting and Finance from Indiana University in 2001....read more